Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
September 21, 2023
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 21, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics Appoints Ian Smith to its Board of Directors
September 20, 2023
– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genet ...Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet ...
September 5, 2023
– Data from multiple ongoing clinical studies of STK-001 show reductions in convulsive seizure frequency and improvements in ...Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 7, 2023
– STK-001: Additional data from patients treated with single and multiple doses (70mg) along with data from open-label extens ...Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 2, 2023
BEDFORD, Mass. --(BUSINESS WIRE)--Aug. 2, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/ ...
July 25, 2023
– Totality of data from these ongoing studies suggest clinical benefit for patients ages 2 to 18 years old, including reducti ...Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies ...
July 21, 2023
BEDFORD, Mass. --(BUSINESS WIRE)--Jul. 21, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 16, 2023
BEDFORD, Mass. --(BUSINESS WIRE)--Jun. 16, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated ...Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 4, 2023
– Company on-track to report new data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents wit ...Stoke Therapeutics to Present at the BofA Securities Health Care Conference
May 3, 2023
BEDFORD, Mass. --(BUSINESS WIRE)--May 3, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to ...